Encore Vision, Inc. Report issue

For profit Phase 2
Founded: Forth Worth TX United States (2000)
Status: Acquired by Novartis (2016)

Organization Overview

First Clinical Trial
2015
NCT02516306
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

ev06 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Presbyopia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1